MPO1 and MPO2 can be regulated for either decreasing or increasing alkaloid levels in plants, in particular in Nicotiana plants. In particular, suppressing or overexpressing one or more of MPO1 and MPO2 may be used to decrease or increase nicotine and nicotinic alkaloid levels in tobacco plants. Suppression or overexpression of one or more of MPO1 and MPO2 may be used in combination with modification of expression of other genes encoding enzymes on the nicotinic alkaloid biosynthetic pathway such as A622, NBB1, PMT, and QPT.

The present application relates to a recombinant microorganism, in which the expression of NADH:quinone oxidoreductase is regulated, and a method for producing O-phosphoserine, cysteine, and cysteine derivatives using the same.

MPO1 and MPO2 can be regulated for either decreasing or increasing alkaloid levels in plants, in particular in Nicotiana plants. In particular, suppressing or overexpressing one or more of MPO1 and MPO2 may be used to decrease or increase nicotine and nicotinic alkaloid levels in tobacco plants. Suppression or overexpression of one or more of MPO1 and MPO2 may be used in combination with modification of expression of other genes encoding enzymes on the nicotinic alkaloid biosynthetic pathway such as A622, NBB1, PMT, and QPT.

The present invention relates to a method for producing a carotenoid-protein complex in vivo comprising the steps of transforming of prokaryote cell with genes involved in carotenoid synthesis and with a gene encoding an apo-carotenoprotein; culturing said prokaryote cells such as to induce sequential genes expression, isolating and purifying the carotenoid-protein complex.

The present invention concerns a metabolically engineered microorganism for glycine bioproduction or a salt or an ester thereof, the genome of said microorganism comprises an attenuation of the expression of genes encoding enzymes having glycine cleavage system activity as defined by E.C. 1.4.1.27 together with an overexpressing of threonine dehydrogenase dependent pathway as defined by EC E.C. 1.1.1.103 and E.C. 2.3.1.29 and/or with a threonine aldolase dependent pathway as defined by E.C. 4.1.2.48 or EC 4.1.2.42 or any of its catalytically active variants, its use for the production of glycine or one of its salts or esters. The present invention also concerns a fermentation process using said metabolically engineered microorganism for the production of glycine or one of its salts or esters.

Provided herein is a method of producing a functional group in a target compound using a biocatalyst as described in more detail herein. Also provided are related systems and compositions.

The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.